Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.[1]

It is a fully human pentameric IgM antibody with a mouse J chain.[1]

Panobacumab molecule consisting of five base units.
1: Base unit.
2: Heavy chains.
3: Light chains.
4: J chain.
5: Intermolecular disulfide bonds.

Development

Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.[2]

The mechanism of action is as a lipopolysaccharide inhibitor.[2]


References

  1. ^ a b International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. ^ a b "Panobacumab - Aridis Pharmaceuticals - AdisInsight". Retrieved 15 November 2019.
Allikas: https://en.wikipedia.org/wiki/Panobacumab
No tags for this post.